Xspray Pharma AB (SE:XSPRAY)
:XSPRAY
Want to see SE:XSPRAY full AI Analyst Report?
XSPRAY Stock Chart & Stats
kr31.20
kr0.60(1.95%)
At close: 4:00 PM EST
kr31.20
kr0.60(1.95%)
Day’s Range― - ―
52-Week Rangekr14.16 - kr62.33
Previous CloseN/A
Volume2.99K
Average Volume (3M)297.70K
Market Cap
kr717.89M
Enterprise Valuekr1.21B
Total Cash (Recent Filing)kr120.72M
Total Debt (Recent Filing)kr147.85M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Aug 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.20
Shares Outstanding47,416,573
10 Day Avg. Volume602,659
30 Day Avg. Volume297,696
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-6.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)11.7
Revenue Forecast (FY)kr91.20M
Bulls Say, Bears Say
Bulls Say
Asset-light Licensing ModelXspray’s model focuses on developing reformulated oncology drugs and monetizing via licensing, milestones and royalties rather than building a sales force. This asset-light, partner-driven approach reduces capital intensity, preserves flexibility and aligns incentives with commercialization partners—durable advantages for a small R&D‑centric biotech.
Proprietary Reformulation TechnologyThe company’s HyNap formulation platform targets tangible clinical/commercial benefits (improved bioavailability, reduced food effect). Proprietary delivery/formulation tech can create sustainable differentiation versus generics and increase partner interest for licensing or label expansion, supporting long‑term dealflow potential.
Equity Cushion And Moderate LeverageA meaningful equity base alongside only moderate leverage provides financial cushion to absorb ongoing R&D losses and fund clinical programs. This capital buffer extends runway, reduces immediate refinancing pressure, and gives management time to advance assets toward partnering or milestone events.
Bears Say
No Revenue, Persistent LossesThe company reports no product revenue and substantial recurring net losses, indicating the business is precommercial and reliant on financing or deals. Without top‑line cash inflows, operational sustainability depends on successful licensing or capital raises, which presents ongoing execution and dilution risk.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow—closely tracking net losses—demonstrate the company burns cash to fund R&D. Cash burn improved versus 2025 but deteriorated versus the prior TTM, signaling uneven progress on discipline and a continuing need for external financing or partner funding to sustain programs.
Rising Debt And Negative ROEDebt has increased markedly from earlier low levels while returns on equity remain deeply negative, indicating equity value erosion. Rising leverage heightens refinancing and interest risks, limits strategic flexibility, and increases the likelihood that future funding will be dilutive or costly if operating losses persist.
Xspray Pharma AB News
XSPRAY FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was kr14.16 and its highest was kr62.33 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is kr717.89M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Aug 05, 2026 which is in 52 days.
How were Xspray Pharma AB’s earnings last quarter?
Currently, no data Available
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in SE:XSPRAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---